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Abstract
Background: We wanted to quantify HLA-A and -B allele and haplotype frequencies in Alabama
hemochromatosis probands with HFE C282Y homozygosity and controls, and to compare results
to those in other populations.
Methods: Alleles were detected using DNA-based typing (probands) and
microlymphocytotoxicity (controls).
Results: Alleles were determined in 139 probands (1,321 controls) and haplotypes in 118
probands (605 controls). In probands, A*03 positivity was 0.7482 (0.2739 controls; p =< 0.0001;
odds ratio (OR) 7.9); positivity for B*07, B*14, and B*56 was also increased. In probands,
haplotypes A*03-B*07 and A*03-B*14 were more frequent (p < 0.0001, respectively; OR = 12.3
and 11.1, respectively). The haplotypes A*01-B*60, A*02-B*39, A*02-B*62, A*03-B*13, A*03-B*15,
A*03-B*27, A*03-B*35, A*03-B*44, A*03-B*47, and A*03-B*57 were also significantly more
frequent in probands. 37.3% of probands were HLA-haploidentical with other proband(s).
Conclusions: A*03 and A*03-B*07 frequencies are increased in Alabama probands, as in other
hemochromatosis cohorts. Increased absolute frequencies of A*03-B*35 have been reported only
in the present Alabama probands and in hemochromatosis patients in Italy. Increased absolute
frequencies of A*01-B*60, A*02-B*39, A*02-B*62, A*03-B*13, A*03-B*15, A*03-B*27, A*03-B*44,
A*03-B*47, and A*03-B*57 in hemochromatosis cohorts have not been reported previously.
Background
Hemochromatosis is common among northwestern Euro-
pean peoples and their descendants. This disorder is typi-
cally associated with homozygosity for the C282Y
mutation of the HFE gene (exon 2, nt 845 GA) on Ch6p
[1]. C282Y lies within an ancestral haplotype which in-
cludes the human leukocyte antigen (HLA) haplotype
A*03-B*07 [2–5]. The ancestral haplotype is the predom-
inant hemochromatosis-associated haplotype in many
northwestern European countries, including Ireland [6],
Brittany [2], Denmark [7,8], Sweden [9], and Germany
[10,11]. This is attributed to the origin of the C282Y mu-
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rope and its early dissemination by Vikings [3,12].
Modification of the ancestral chromosome by recombina-
tion and admixture as a result of geographic migration ex-
plains the occurrence of chromosomes bearing C282Y in
association with different HLA haplotypes [2,4,8,13–16].
Thus some non-ancestral haplotypes also occur with sig-
nificantly increased frequencies in hemochromatosis pa-
tients in various countries in Europe and in descendants
of Europeans [5,16].
In North America, phenotype frequencies of HLA alleles
in persons with hemochromatosis and in control popula-
tions have been reported from Canada, Utah, and Minne-
sota [17–19]. HLA haplotype frequencies for
hemochromatosis patients and control subjects in North
America have been reported only from Utah [20]. The
purpose of the present work was to quantify and analyze
the frequencies of HLA-A and -B alleles and haplotypes in
hemochromatosis probands with C282Y homozygosity
in central Alabama, and to compare the present results to




The performance of this work was approved by the Insti-
tutional Review Boards of Brookwood Medical Center and
the University of Alabama at Birmingham. A presumptive
diagnosis of hemochromatosis was established using an
elevated transferrin saturation criterion; each proband
was subsequently evaluated for iron overload and its com-
plications [21–23]. All probands in the present study were
white adults (> 18 years of age). Probands were included
who had: a) diagnosis of hemochromatosis in routine
medical care during the interval 1997 – 2001; b) C282Y
homozygosity; c) available HLA-A and -B typing; and d)
residence in central Alabama. No patient declined to un-
dergo HFE mutation analysis after it was determined that
he/she had a hemochromatosis phenotype. There were A
and B typing data in 139 probands. Haplotypes could not
be determined in 21 probands due to similarities in alleles
of probands and family members, or due to unavailability
of family members for analysis. Thus, there were haplo-
type data on 118 probands.
Control subjects
Data from 1,321 apparently normal, unrelated white
adult subjects from Alabama who had undergone A and B
phenotype analysis as part of paternity testing were used
to estimate allele and gene frequencies [[21]; R.T. Acton,
unpublished observations]. A and B haplotypes were de-
termined in 605 unrelated white subjects from Alabama
(children and their mothers and/or putative fathers) who
had undergone testing to establish paternity.
Laboratory methods
Serum iron concentration, transferrin saturation, and se-
rum ferritin concentration were measured using automat-
ed clinical methods. Sections of liver biopsy specimens
were stained using hematoxylin and eosin, Masson's tri-
chrome, and Perls' Prussian blue techniques; intrahepato-
cytic iron was graded according to the method of Scheuer
et al. [24].
HFE mutation analysis was performed as previously de-
scribed [23]. A and B alleles were detected using low-reso-
lution DNA-based typing (PCR/sequence-specific
oligonucleotide probe) in probands [23]. Control sub-
jects were tested using the microdroplet lymphocytotoxic-
ity test [25]; subjects were evaluated using antisera that
detected allele assignments described in the 9th Interna-
tional Histocompatibility Workshop [26]. Because the
levels of resolution of the DNA-based and serological typ-
ing methods we used are similar, alleles detected by these
respective methods provide concordant allele assign-
ments, with the exception of B*70 and B*71 that were not
detected by serological methods. HFE mutation analysis
and HLA typing of family members were performed to
permit assignment of Ch6p haplotypes. In each proband
in whom a single A or B allele was detected by DNA-based
typing, we verified the allele(s) and set phase to ascertain
haplotypes of the proband using HFE and HLA analyses of
appropriate family members. For the present analysis, all
haplotypes were defined only by A and B alleles, and the
ancestral haplotype was defined as a hemochromatosis-
associated Ch6p bearing A*03-B*07 and HFE C282Y.
Literature review
For most comparisons, recent tabulations of A and B allele
associations in 21 case-control studies from thirteen
countries and A and B haplotype analyses in persons with
hemochromatosis and control subjects in eight countries
or regions were used [16]. We also made computerized
and manual searches to identify estimates of the preva-
lence of C282Y homozygosity in hemochromatosis cases
in various countries or regions for which A and B haplo-
type data were also available.
Statistical considerations
A data set that included HLA types in 139 probands and
haplotypes in 118 probands was available. Absolute or
"uncorrected" values of A and B phenotype frequencies in
probands, respective frequencies of A and B genes, A and
B haplotype frequencies, and occurrence of two-haplo-
type combinations were calculated after enumeration of
the raw data. Some previously reported hemochromato-
sis-associated HLA broad specificities are designated here-
in as corresponding splits (A*09 = A*23 and A*24; B*05
= B*51 and B*52; and B*12 = B*44 and B*45, respective-
ly) [26]. A computer spreadsheet (Excel 2000, MicrosoftPage 2 of 8
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v. 8.0 2000, Dynamic Microsystems, Inc., Silver Spring,
MD) were used to perform the present analyses. Frequen-
cy values were compared using chi-square analysis or one-
tail Fisher's exact test, as appropriate. A value of p < 0.05
was defined as significant, and these values were ex-
pressed to four significant figures. Odds ratios (OR) were
calculated as previously described [27]. Bonferroni's cor-
rection for multiple tests was not performed because
many of the HLA associations with hemochromatosis re-
ported herein have been described elsewhere.
Results
Hemochromatosis probands
There were 87 men ages 51  4 years (mean  1 S.D.) and
52 women ages 50  5 years. Iron overload was detected
using serum ferritin concentration, hepatic iron index, or
quantitative phlebotomy in 135 probands; three women
and one man had no evidence of iron overload. Twenty-
six probands (20 men, 6 women) had hepatic cirrhosis
demonstrated by hepatic biopsy. Eighteen probands (12
men, 6 women) had diabetes mellitus. Thirteen men had
hypogonadotrophic hypogonadism. Cardiomyopathy at-
tributable to iron overload was not diagnosed in any
proband.
Phenotype frequencies of HLA-A and -B alleles
Fourteen A alleles were detected in 139 probands (Table
1). Sixteen A alleles were detected in control subjects. The
most frequent A alleles in probands were A*02 (0.3021),
A*03 (0.7482), and A*11 (0.1007). The frequency of
A*03 was greater in probands than in control subjects (p
< 0.0001, OR 7.9). A*01 and A*02 occurred with signifi-
cantly lower frequencies in probands than in control sub-
jects (Table 1).
Twenty-five B alleles were detected in 139 probands (Ta-
ble 2) [Additional file 1]. Thirty-four B alleles were detect-
ed in control subjects. The most frequent B alleles in
probands were B*07 (0.4748), B*08 (0.1655), B*14
(0.1942), and B*44 (0.2590). The frequencies of B*07,
B*14, and B*56 were greater in probands than those in
the control subjects (p < 0.0001, OR = 2.6; p < 0.0001, OR
= 3.5; and p = 0.0325, OR = 3.8, respectively). B*08 and
B*35 occurred with significantly lower frequencies in
probands than in control subjects (Table 2) [Additional
file 1]. Because arthropathy is common in persons with
hemochromatosis [28], we compared the frequencies of
B*27 in probands and control subjects; the difference was
not significant (Table 2) [Additional file 1].
Frequencies of HLA-A and -B alleles
Gene frequencies corresponding to A*01 and A*02 were
significantly lower in probands than in control subjects (p
= 0.0014, OR = 0.5 and p < 0.0001, OR = 0.5, respective-
ly). A*03 was significantly more frequent in probands
than in control subjects (p < 0.0001, OR = 6.1). Some
probands were homozygous for A alleles by DNA-based
typing and family studies: A*01 (n = 2), A*02 (n = 7),
A*03 (n = 29), A*11 (n = 1), A*24 (n = 1), and A*24 (n
= 1). The B*07 and B*14 gene frequencies were signifi-
cantly greater in probands than in control subjects (p <
Table 1: Phenotype Frequencies of HLA-A Alleles in Alabama Subjects.1
A* Alleles Frequency in 139 Hemochromatosis Probands Frequency in Control Subjects (n) Odds Ratio
01 0.20142 0.3397 (1,319) 0.5
02 0.30212 0.5206 (1,310) 0.4
03 0.74823 0.2739 (1,318) 7.9
11 0.1007 0.1136 (1,320) 0.9
23 0.0288 0.0375 (1,254) 0.9
24 0.0719 0.1304 (1,265) 0.5
25 0.0432 0.0297 (1,281) 1.5
26 0.0216 0.0634 (1,278) 0.3
28 0.0504 0.0773 (1,320) 0.6
29 0.0432 0.0620 (1,290) 0.7
30 0.0144 0.0405 (1,308) 0.4
31 0.0216 0.0350 (1,258) 0.6
32 0. 0216 0.0536 (1,232) 0.4
33 0. 0216 0.0176 (1,248) 1.2
1Alleles were detected using low-resolution DNA-based typing in hemochromatosis probands and microlymphocytotoxcity in control subjects. 
2These frequencies were significantly lower in hemochromatosis probands than in control subjects (A*01, p = 0.0013; A*02, p < 0.0001). 3This fre-
quency in hemochromatosis probands was significantly greater in probands than in control subjects (p < 0.0001).Page 3 of 8
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In addition, the B*56 allele was more frequent in
probands (p = 0.0330, OR = 3.8). The B*35 allele was sig-
nificantly less frequent in probands than in control sub-
jects (p = 0.0159, OR = 0.4). Some probands were
homozygous for B alleles by DNA-based typing and fam-
ily studies: B*07 (n = 13), B*08 (n = 3), B*37 (n = 1),
B*44 (n = 2), and B*51 (n = 1).
HLA-A and -B haplotypes
Seventy-two different haplotypes were detected in 118
probands and 133 haplotypes were detected in control
subjects. Twenty-three haplotypes detected in probands
were not observed in control subjects (Table 3) [Addition-
al file 2].
The most frequent haplotypes in probands were A*01-
B*08 (frequency 0.0720); A*02-B*44 (0.0508); A*03-
B*07 (0.2966); and A*03-B*14 (0.0847). A*03-B*07 and
A*03-B*14 were significantly more frequent in probands
than in control subjects (p < 0.0001, respectively; OR =
12.3 and 11.1, respectively) (Table 3) [Additional file 2].
Fifty-eight probands (48.2%) inherited the ancestral hap-
lotype defined as A*03-B*07, HFE C282Y; 46 were heter-
ozygous and 12 were homozygous for the haplotype.
Other haplotypes were also significantly more frequent in
probands than in control subjects: A*01-B*60, A*02-
B*39, A*02-B*62, A*03-B*13, A*03-B*15, A*03-B*27,
A*03-B*35, A*03-B*44, A*03-B*47, and A*03-B*57 (Ta-
ble 3) [Additional file 2]. The combined frequencies of
these ten haplotypes in probands was 0.1441 and in con-
trol subjects was 0.0033 (p < 0.0001). The frequencies of
haplotypes which included B*07 or B*14 without A*03
were not significantly different in probands and control
subjects (Table 3) [Additional file 2]. Homozygosity for
these haplotypes was observed in some probands: A*01-
B*08 (n = 1); A*02-B*07 (n = 1); A*02-B*44 (n = 1); and
A*03-B*07 (n = 12).
Forty-four of 118 probands (37.3%) were HLA-haploi-
dentical with at least one other proband in the present
study. Thirty-four of the 44 probands (77.3%) had the
A*03-B*07 haplotype (Table 4). Four had the haplotypes
A*02-B*39, A*03-B*13, or A*03-B*44. Altogether, four-
teen different haplotypes defined by A and B typing oc-
curred in these 44 probands (Table 4).
Comparison of Alabama hemochromatosis probands with 
persons with hemochromatosis in other locations
HLA-A and -B alleles
We compared the present results with data in a previously
published tabulation of A and B allele associations in 21
case-control studies from 13 countries or regions in Eu-
rope, Australia, and North America [16]. This tabulation
yielded a mean A*03 phenotype frequency of 0.75 (range
0.53 – 0.83) in hemochromatosis patients and 0.25
(range 0.19 – 0.31) in control subjects [16]. In Alabama
subjects, therefore, the A*03 phenotype frequencies in
probands (0.7482) and control subjects (0.2739) were
similar to the corresponding mean values previously tab-
ulated [16]. However, the OR for hemochromatosis asso-
ciated with A*03 in Alabama probands (7.9) was
somewhat greater than the corresponding mean value of
Table 4: HLA Haploidentical Alabama Hemochromatosis Probands.1
Haplotype 1 Haplotype 2 Observed Frequency of Probands (no. of 
probands)
A*01-B*08 A*02-B*44 0.0169 (2)
A*03-B*07 0.0339 (4)
A*03-B*14 0.0254 (3)
A*02, B*39 A*03-B*07 0.0169 (2)
A*02-B*44 A*03-B*07 0.0169 (2)
A*02-B*60 A*03-B*07 0.0254 (3)






A*03-B*13 A*03-B*44 0.0169 (2)
A*03-B*14 A*03-B*47 0.0254 (3)
1These two-haplotype matches were detected in 44 of 118 white hemochromatosis probands (236 chromosomes) who resided in central Alabama.Page 4 of 8
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15.1; 95% confidence interval 5.7 – 7.6) [16].
HLA-A and -B haplotypes
We compared the present results with data in a previously
published tabulation of A and B haplotypes which oc-
curred with significantly greater frequency in hemochro-
matosis patients than in corresponding control patients;
data were available from Germany, Denmark, Sweden,
Brittany, Portugal, Italy, Australia, and Utah (Table 5)
[Additional file 3] [16][31]. Frequencies of the A*03-B*07
haplotype were increased in all hemochromatosis patient
groups. The frequencies of the A*03-B*14 haplotype were
significantly increased in persons with hemochromatosis
in Brittany, Sweden, Utah, and Alabama (Table 5) [Addi-
tional file 3] [31]. A significantly increased absolute fre-
quency of the haplotype A*03-B*35 occurred in Alabama
probands and in hemochromatosis patients in Italy [29].
A significantly increased frequency of the haplotype A*03-
B*15 was observed in the present Alabama hemochroma-
tosis probands; a relative increase in this haplotype was
detected in hemochromatosis cohorts in Brittany and
Utah [2,20]. A significantly increased frequency of the
haplotype A*03-B*44 was observed in the present Ala-
bama hemochromatosis probands, whereas a relative in-
crease in this haplotype was reported in hemochromatosis
cohorts in Sweden, Brittany, and Utah only after "correc-
tion" of the data for the preponderance of other haplo-
types (Table 5) [Additional file 3] [31]. The increased
frequencies of the A*01-B*60, A*02-B*39, A*02-B*62,
A*03-B*13, A*03-B*27, A*03-B*47, and A*03-B*57
haplotypes observed in Alabama probands in the present
study were not reported in persons with hemochromato-
sis in the seven other countries for which data were avail-
able (Table 5) [Additional file 3] [31].
Discussion
A*03 positivity was detected in more than 74% of Ala-
bama C282Y homozygous hemochromatosis probands in
the present study. Similarly, the frequency of A*03 posi-
tivity was significantly increased in Alabama hemochro-
matosis probands diagnosed before the discovery of
HFE[21]. These observations are consistent with and ex-
tend the findings of 21 previously reported case-control-
led studies from thirteen countries which demonstrate the
significantly increased prevalence of A*03 in persons with
hemochromatosis [16]. The alleles B*07 and B*14 were
also more common in the present Alabama probands and
in Alabama probands diagnosed before discovery of HFE
than in corresponding control subjects [21]. The present
analysis demonstrates that this is attributable largely to
the association of B*07 and B*14 with A*03, consistent
with observations in persons with hemochromatosis pa-
tients from many locations, including Ireland [6], Brittany
[2,32–34], Denmark [7,8], Sweden [9,35,36], Germany
[10,11,37,38], Portugal [30,39], Italy [2,40], and Utah
[20].
The frequency of the ancestral haplotype defined by A*03-
B*07 in the present Alabama probands is greater than that
reported in persons with hemochromatosis reported from
most other areas. It is possible that our method of selec-
tion of subjects for the present study could partly account
for this. We selected only probands who had a hemochro-
matosis phenotype and C282Y homozygosity. Across oth-
er studies of HLA haplotypes in subjects with
hemochromatosis, criteria for definition of hemochroma-
tosis phenotypes differed. Some studies included
probands, whereas others included probands and all fam-
ily members with hemochromatosis; some required dem-
onstration of segregation with HLA haplotypes, and
others did not [33–43]. None used HFE mutation analysis
as an inclusion criterion as we required in the present
study. In several countries in northwestern Europe, how-
ever, the percentage of C282Y homozygotes in hemochro-
matosis case series is greater than 90% [33–35,37,38]. In
Queensland, a frequency of C282Y homozygosity of
100% was reported among patients identified by pheno-
type criteria [42]. Thus, the selection criterion of C282Y
homozygosity in the present study nonetheless resulted in
a group of hemochromatosis probands the HFE genotypes
of which are similar to those of hemochromatosis patients
of northwestern European descent in other studies.
The absolute frequencies of haplotypes A*01-B*60, A*02-
B*39, A*02-B*62, A*03-B*13, A*03-B*15, A*03-B*27,
A*03-B*35, A*03-B*44, A*03-B*47, and A*03-B*57 (in
addition to A*03-B*07 and A*03-B*14 haplotypes) were
significantly greater in Alabama probands than in control
subjects. A significantly increased absolute frequency of
the haplotype A*03-B*35 has also been reported in he-
mochromatosis patients in Italy [29]. The present obser-
vations regarding this haplotype may be attributable to
the large subgroup of persons of Italian and Sicilian de-
scent in central Alabama [44]. A significantly increased
frequency of the haplotype A*03-B*15 was observed in
the present Alabama hemochromatosis probands, where-
as a relative increase in this haplotype was detected in he-
mochromatosis cohorts in Brittany and Utah only after
"correction" of the data for the preponderance of other
haplotypes [2,20]. Similarly, a significantly increased fre-
quency of the haplotype A*03-B*44 was observed in the
present Alabama hemochromatosis probands, whereas a
relative increase in this haplotype was detected in hemo-
chromatosis cohorts in Sweden, Brittany, and Utah after
"correction" of the data for the preponderance of other
haplotypes [2,8,19]. The absolute frequency of the haplo-
type A*03-B*47 was increased in central Alabama hemo-
chromatosis probands, whereas a "corrected" frequency of
A*03-B*47 was increased in hemochromatosis patientsPage 5 of 8
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(except A*03-B*07 and A*03-B*14) have not been re-
ported to occur with increased frequency in any hemo-
chromatosis cohort from locations other than Alabama.
Thus, we observed a greater number of haplotypes which
were significantly increased in frequency among the
present Alabama hemochromatosis probands than have
been reported in other hemochromatosis populations, in-
cluding a cohort in Utah [16]. This could be attributed to
a greater degree of genetic heterogeneity among whites in
Alabama, consistent with previous reports of genetic char-
acteristics of persons with hemochromatosis in this geo-
graphic area [23,45]. Alternatively, we had greater power
to achieve statistical significance in the present analyses
than did some other studies. Nonetheless, the percentage
of the present probands who were HLA-haploidentical
with at least one other proband indicates that the haplo-
types among hemochromatosis patients in central Ala-
bama are more restricted than those in the general
population [46,47].
In Alabama subjects with hemochromatosis, the A*03-
B*07 haplotype is not invariably associated with inherit-
ance of C282Y. The frequency of the A*03-B*07 haplo-
type was significantly increased in Alabama
hemochromatosis probands without C282Y [23], some of
whom had the common HFE missense mutation H63D
[23]. A*03-B*07 haplotypes associated with H63D have
also been described in Alabama subjects with primary an-
tibody deficiency [48]. Some Alabama subjects with he-
mochromatosis have an A*03-B*07 haplotype which
includes the novel HFE missense mutation I105T [48].
Thus, a variety of HFE missense mutations occur in asso-
ciation with A*03-B*07 haplotypes in white Alabamians.
Conclusions
A*03 and A*03-B*07 frequencies are increased in Ala-
bama probands, like other hemochromatosis cohorts. In-
creased absolute frequencies of the haplotype A*03-B*35
have been reported only in the present Alabama probands
and in hemochromatosis patients in Italy. Increased abso-
lute frequencies of A*01-B*60, A*02-B*39, A*02-B*62,
A*03-B*13, A*03-B*15, A*03-B*27, A*03-B*44, A*03-
B*47, and A*03-B*57 were detected in the present cohort
of Alabama hemochromatosis probands, but these haplo-
types have not been reported to occur with increased ab-
solute frequency in other hemochromatosis populations.
Modification of the ancestral chromosome by recombina-
tion and admixture as a result of geographic migration
could explain the previously undescribed occurrence of
HLA haplotypes that occur in association with C282Y.
These results could also be explained by the greater degree
of genetic heterogeneity in white Alabamians than in oth-
er populations, and by the larger numbers of probands
and control subjects and greater statistical power to dem-
onstrate significant differences in the present study than
in some similar previous studies. A variety of HFE mis-
sense mutations occur in association with A*03-B*07
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